Aberdeen Group’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $14.9M | Sell |
118,286
-102,058
| -46% | -$12.8M | 0.03% | 496 |
|
|
2025
Q1 | $24.4M | Buy |
220,344
+63,770
| +41% | +$7.05M | 0.05% | 341 |
|
|
2024
Q4 | $21.4M | Buy |
156,574
+20,150
| +15% | +$2.75M | 0.04% | 357 |
|
|
2024
Q3 | $15.7M | Sell |
136,424
-24,723
| -15% | -$2.85M | 0.03% | 438 |
|
|
2024
Q2 | $22.2M | Buy |
161,147
+77,935
| +94% | +$10.7M | 0.04% | 357 |
|
|
2024
Q1 | $11.5M | Sell |
83,212
-421
| -0.5% | -$58.1K | 0.02% | 525 |
|
|
2023
Q4 | $11M | Buy |
83,633
+80,420
| +2,503% | +$10.6M | 0.02% | 530 |
|
|
2023
Q3 | $361K | Sell |
3,213
-269
| -8% | -$30.3K | ﹤0.01% | 843 |
|
|
2023
Q2 | $328K | Buy |
3,482
+1,504
| +76% | +$142K | ﹤0.01% | 866 |
|
|
2023
Q1 | $200K | Buy |
+1,978
| New | +$200K | ﹤0.01% | 899 |
|
|
2021
Q2 | – | Sell |
-3,419
| Closed | -$333K | – | 1028 |
|
|
2021
Q1 | $333K | Buy |
3,419
+255
| +8% | +$24.8K | ﹤0.01% | 942 |
|
|
2020
Q4 | $303K | Buy |
3,164
+346
| +12% | +$33.1K | ﹤0.01% | 924 |
|
|
2020
Q3 | $271K | Sell |
2,818
-2,283
| -45% | -$220K | ﹤0.01% | 904 |
|
|
2020
Q2 | $622K | Sell |
5,101
-76,461
| -94% | -$9.32M | ﹤0.01% | 837 |
|
|
2020
Q1 | $7.06M | Sell |
81,562
-695
| -0.8% | -$60.2K | 0.02% | 457 |
|
|
2019
Q4 | $8.84M | Buy |
82,257
+1,569
| +2% | +$169K | 0.02% | 483 |
|
|
2019
Q3 | $7.27M | Sell |
80,688
-19,608
| -20% | -$1.77M | 0.02% | 514 |
|
|
2019
Q2 | $8.47M | Sell |
100,296
-4,719
| -4% | -$399K | 0.02% | 549 |
|
|
2019
Q1 | $9.25M | Sell |
105,015
-5,565
| -5% | -$490K | 0.02% | 524 |
|
|
2018
Q4 | $7.82M | Sell |
110,580
-26,127
| -19% | -$1.85M | 0.02% | 491 |
|
|
2018
Q3 | $16.8M | Buy |
+136,707
| New | +$16.8M | 0.03% | 411 |
|